1,109 United Therapeutics Corporation $UTHR Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 1.3% in the 3rd quarter, Holdings Channel reports. The firm owned 84,387 shares of the biotechnology company’s stock after selling 1,109 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in United Therapeutics were worth $45,728,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Arjuna Capital lifted its position in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares in the last quarter. Sage Rhino Capital LLC boosted its position in United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after buying an additional 23 shares during the last quarter. Bryn Mawr Trust Advisors LLC raised its position in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares during the period. Meeder Advisory Services Inc. boosted its holdings in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after buying an additional 26 shares during the last quarter. Finally, Kera Capital Partners Inc. increased its position in United Therapeutics by 6.1% during the first quarter. Kera Capital Partners Inc. now owns 471 shares of the biotechnology company’s stock worth $279,000 after acquiring an additional 27 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

United Therapeutics stock opened at $608.49 on Thursday. United Therapeutics Corporation has a 1 year low of $432.53 and a 1 year high of $614.23. The firm has a market cap of $26.10 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 4.35 and a beta of 0.49. The firm’s 50 day moving average price is $532.33 and its two-hundred day moving average price is $532.45.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. During the same quarter in the previous year, the business posted $7.16 EPS. The firm’s quarterly revenue was up 4.1% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.09 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has authorized a stock buyback plan on Thursday, October 22nd that authorizes the company to repurchase $2 billion in shares. This repurchase authorization authorizes the biotechnology company to reacquire up to 8.3% of its shares through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at approximately $170,968,483.28. This represents a 2.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 393,228 shares of company stock valued at $207,340,321. 8.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. The Goldman Sachs Group restated a “sell” rating and set a $368.00 price objective on shares of United Therapeutics in a report on Thursday, October 15th. Morgan Stanley raised their price target on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a report on Wednesday, October 7th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price target on shares of United Therapeutics in a research report on Monday, October 26th. Jefferies Financial Group reissued a “buy” rating and issued a $728.00 price target on shares of United Therapeutics in a research note on Wednesday, October 14th. Finally, Leerink Partners lifted their target price on United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $674.00.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, beating analyst expectations of about $781 million. Management said the company is entering a period of stronger growth and advancing new therapies. United Therapeutics Q3 2026 results
• Positive Sentiment: BTIG raised its price target to $768 from $728 and maintained a Buy rating, signaling continued analyst confidence in the shares. BTIG Research ratings
• Positive Sentiment: The company announced a buyout of Pfizer’s royalty rights tied to ralinepag, a lung-disease therapy. Ending those royalties could improve the drug’s future economics, though the announcement details provided no financial terms. Ralinepag royalty buydown announcement
• Negative Sentiment: Adjusted earnings were a weak spot: EPS of $5.71 missed the approximately $6.01 consensus and fell from $7.16 a year earlier. Reports also noted lower net income. Q3 earnings miss
• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares, reducing her direct holding by 2.84%. She retained 324,443 shares; the sale may draw investor attention but does not by itself establish a change in the company’s outlook. United Therapeutics insider trades

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.